| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -197,667 | -123,551 |
| Share-based compensation expense | 25,756 | 14,791 |
| Depreciation expense | 629 | 465 |
| Non-cash interest expense | 412 | 271 |
| Amortization of premium and accretion of discounts on short-term investments, net | 7,106 | 5,182 |
| Contract liabilities | 39,427 | 23,763 |
| Accounts payable and accrued expenses | 14,814 | 2,098 |
| Other long-term liabilities | 925 | 628 |
| Receivable from contracts with collaborators | 33,876 | 2,514 |
| Prepaid expenses and other current assets | 18,840 | 8,551 |
| Operating lease right-of-use and other long-term assets | 5,805 | 2,922 |
| Net cash used in operating activities | -181,331 | -100,704 |
| Maturities of short-term investments | 577,628 | 342,596 |
| Purchases of short-term investments | 521,813 | 383,314 |
| Purchases of property and equipment | 4,317 | 1,750 |
| Net cash provided by (used in) investing activities | 51,498 | -42,468 |
| Proceeds from issuance of stock under equity plans | 658 | 658 |
| Net cash provided by financing activities | 658 | 658 |
| Net increase (decrease) in cash and cash equivalents | -129,175 | -142,514 |
| Cash and cash equivalents at beginning of period | 224,462 | - |
| Cash and cash equivalents at end of period | 95,287 | - |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)